Asia
The big Connect in Pharma conference is coming up with digitization and supply chain on the agenda and CanSino Biologics, HUTCHMED and more have positive research news.
The agreement will grant Innovent exclusive development and marketing rights to tusamitamab in China, while Sanofi will be entitled to up to $81 million in milestones and royalties.
Here’s a look at global biopharma company news stories including Rona Therapeutics, Genuine Bio and NEOsphere Bio.
In 2000, China did not have one company on the Forbes Global 2000 list. In 2021, it had 14. This is good for second place on this list, behind the United States which had 31.
Maxvax and Luzhu are raising funds to move their respective research and development programs for recombinant herpes zoster vaccine candidates and new adjuvant products.
Beigene and Novartis announced the FDA has deferred action on the BLA for tislelizumab until inspections of facilities in China can be completed.
Many healthcare, pharmaceutical and biotech companies continue to place their bets on China, bringing fresh rounds of investments to and forging new partnerships with local firms.
The $1.6-billion infusion into its subsidiary is Fujifilm’s latest move to establish a more robust presence in the cell culture manufacturing space.
AstraZeneca had a very busy week of international news, with progress being shown in China, positive recommendations for two drugs in Europe and a positive clinical trial update.
Ascletis has commenced its Phase II trial in China for its candidate drug ASC22 alongside anti-retroviral therapy for the functional cure and immune restoration of HIV-1 infection.
PRESS RELEASES